Personalized medicine in the age of pharmacoproteomics: A close up on India and need for social science engagement for responsible innovation in post-proteomic biology

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 3, 2011, Pages 159-167

  Reddy, Panga Jaipal ^a   Jain, Rekha ^a   Paik, Young Ki ^b   Downey, Robin ^c   Ptolemy, Adam S ^d   Ozdemir, Vural ^e   Srivastava, Sanjeeva ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b Yonsei University   (South Korea)

^c Genome British Columbia   (Canada)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Human proteome project; India; Knowledge based innovation; Personalized medicine; Pharmacoproteomics; Protein microarrays; South asia and diagnostic medicine; Upstream technology assessment

Indexed keywords

ANTIBODY; DNA; PROTEIN; PROTEOME;

CLINICAL PHARMACOLOGY; DNA MICROARRAY; EDITORIAL; GEOGRAPHIC DISTRIBUTION; HUMAN; INDIA; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; PERSONALIZED MEDICINE; PHARMACOPROTEOMICS; PROTEIN MICROARRAY; PROTEOMICS; SOCIOLOGY;

EID: 80052251753     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569211796957557     Document Type: Editorial

References (57)

1. Anderson NG, Matheson A, Anderson NL. Back to the future: the human protein index (HPI) and the agenda for post-proteomic biology. Proteomics 2001; 1: 3-12.
2. Legrain P, Aebersold R, Archakov A, et al. The human proteome project: Current state and future direction. Mol Cell Proteomics 2011 Apr 29 [Epub ahead of print].
3. Paik YK, Kim H, Lee EY, et al. Overview and introduction to clinical proteomics. Methods Mol Biol 2008; 428: 1-31.
4. Kalow W, Ozdemir V, Tang BK, et al. The science of pharmacological variability: an essay. Clin Pharmacol Ther 1999; 66(5): 445-447.
5. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of edge effect and cultivating an ethical bridge between omics innovations and society. OMICS 2009; 13(1): 43-61.
6. Armengaud J. Proteogenomics and systems biology: quest for the ultimate missing parts. Expert Rev Proteomics 2010; 7(1): 65-77.
7. Ozdemir V, Armengaud J, Dubé L, et al. Nutriproteomics and proteogenomics: cultivating two novel hybrid fields of personalized medicine with added societal value. Curr Pharmacogenomics Person Med 2010; 8(4): 240-244. Available from: http://www.benthamscience.com/openaccessplus.php?JCode=CPPM [Accessed June 27, 2011].
8. National Science Foundation. Office of Cyberinfrastructure. Advisory Committee for Cyberinfrastucture (ACCI) Task Force Reports, 2011. Available from: http://www.nsf.gov/od/oci/taskforces/[Accessed June 27, 2011].
9. Kolker E, Higdon R, Welch D, et al. SPIRE: Systematic protein investigative research environment. J Proteomics 2011 May 13 [Epub ahead of print].
10. Ommer R, Wynne B, Downey R, et al. Pathways to Integration. Vancouver: Genome British Columbia GSEAC Subcommittee on Pathways to Integration, 2011. Available from: www.genomebc.ca/index.php/download_file/view/611/910/ [Accessed on June 27, 2011].
11. The Hindu, Business Line. Focus on Gene Chips and Proteomics, Says Kalam. Aug 06, 2005. Available from: http://www.hinduonnet.com/thehindu/thscrip/print.pl?file=2005080601180300.htm&date=2005/08/06/&prd=bl&[Accessed on June 27, 2011].
12. Chumbalkar VC, Subhashini C, Dhople VM, et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005; 5: 1167-1177.
13. Kumar DM, Thota B, Shinde SV, et al. Proteomic identification of Haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res 2010; 9: 5557-5567.
14. Govekar RB, D'Cruz AK, Pathak KA, et al. Proteomic profiling of cancer of the gingivo-buccal complex: Identification of new differentially expressed markers. Proteomics Clin Appl 2009; 3: 1451-1462.
15. Mallikarjuna K, Sundaram CS, Sharma Y, et al. Comparative proteomic analysis of differentially expressed proteins in primary retinoblastoma tumors. Proteomics Clin Appl 2010; 4(4): 449-463.
16. Faridi U, Sisodia BS, Shukla AK, et al. Proteomics indicates modulation of tubulin polymerization by L-menthol inhibiting human epithelial colorectal adenocarcinoma cell proliferation. Proteomics 2011; 11(10): 2115-2119.
17. Pal P, Kanaujiya JK, Lochab S, et al. 2-D gel electrophoresis-based proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest and ERK-mediated apoptosis in chronic myeloid leukemia cells K562. Proteomics 2011; 11(8):1517-1529.
18. Kashyap MK, Harsha HC, Renuse S, et al. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther 2010; 10(8): 796-810.
19. Marimuthu A, O'Meally RN, Chaerkady R, et al. A comprehensive map of the human urinary proteome. J Proteome Res 2011; 10(6): 2734-2743.
20. Daar AS. Chronic noncommunicable diseases as a threat for all: recent global initiatives. Sultan Qaboos Univ Med J 2010; 10(3): 306-309.
21. Ranjan R, Chugh M, Kumar S, et al. Proteome analysis reveals a large merozoite surface protein-1 associated complex on the Plasmodium falciparum merozoite surface. J Proteome Res 2011; 10(2): 680-691.
22. Acharya P, Pallavi R, Chandran S, et al. A glimpse into the clinical proteome of human malaria parasites Plasmodium falciparum and Plasmodium vivax. Proteomics Clin Appl 2009; 3: 1314-1325.
23. Gupta SK, Sisodia BS, Sinha S, et al. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 2007; 7(5): 816-823.
24. Gautam P, Shankar J, Madan T, et al. Proteomic and transcriptomic analysis of Aspergillus fumigatus on exposure to amphotericin B. Antimicrob Agents Chemother 2008; 52: 4220-4227.
25. Rao PV, Reddy AP, Lu X, et al. Proteomic Identification of salivary biomarkers of Type-2 Diabetes. J Proteome Res 2009; 8: 239-245.
26. Singh OV, Vij N, Mogayzel PJ Jr, et al. Pharmacoproteomics of 4- phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. J Proteome Res 2006; 5(3): 562-571.
27. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000; 289(5485): 1760-1763.
28. Chandra H, Reddy PJ, Srivastava S. Protein microarrays and novel detection platforms. Expert Rev Proteomics 2011; 8(1): 61-79.
29. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem 2010; 56: 212-222.
30. Rahbar A, Rivers R, Boja E, et al. Realizing individual medicine: the road to translating proteomics from the laboratory to the clinic. Personal Med 2011; 8: 45-57.
31. Korean Pharmacogenomics Research Network. Available from: http://www.pharmacogenomics.or.kr/english/introduction.php [Accessed on June 27, 2011].
32. The Knowledge Base for Korean Pharmacogenomics Research Network. Available from: http://kpgrn.snubi.org/index.html [Accessed on June 27, 2011].
33. Park CS, Rhim T. Application of proteomics in asthma research. Expert Rev Proteomics 2011; 8: 221-230.
34. Chung HK, Chae JS, Hyun YJ, et al. Influence of adiponectin gene polymorphisms on adiponectin level and insulin resistance index in response to dietary intervention in overweight-obese patients with impaired fasting glucose or newly diagnosed type 2 diabetes. Diabetes Care 2009; 32: 552-558.
35. Bang JY, Kim EY, Kang DK, et al. Pharmaco-proteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis. Mol Cell Proteomics 2011; May 10 [Epub ahead of print].
36. Kwon MH, Kong DH, Jung SH, et al. Rapid determination of blood coagulation factor XIII activity using protein arrays for serodiagnosis of human plasma. Anal Chem 2011; 83: 2317-2323.
37. Verrills NM, Liem NL, Liaw TY, et al. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study. Proteomics 2006; 6: 1681-1694.
38. Sung FL, Pang RT, Ma BB, et al. Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma. J Proteome Res 2006; 5: 3260-3267.
39. Su B, Yang YB, Tuo QH, et al. Anti-apoptotic effects of probucol are associated with down regulation of Daxx expression in THP-1 macrophage. Cardiovasc Drugs Ther 2007; 21: 37-45.
40. Suehara Y, Tochigi N, Kubota D, et al. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics 2011; 74: 829-842.
41. Saminathan R, Bai J, Sadrolodabaee L, et al. VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker. PLoS One 2010; 5(12): e15064.
42. Ozdemir V, Muljono DH, Pang T, et al. Asia-Pacific Health 2020 and genomics without borders: co-production of knowledge by science and society partnership for global personalized medicine. Curr Pharmacogenomics Person Med 2011; 9(1): 1-5. Available from: http://www.benthamscience.com/cppm/openaccessarticles/cppm9-1/001AF.pdf [Accessed June 27, 2011].
43. Böhme G, Stehr N. The Knowledge Society. Reidel: Dordrecht 1986.
44. Fisher E, Mahajan RL, Mitcham C. Midstream modulation of technology: governance from within. Bull Science Technol Soc 2006; 26: 485-496.
45. Guston DH. Innovation policy: not just a jumbo shrimp. Nature 2008; 454(7207): 940-941.
46. Ozdemir V, Knoppers BM. From government to anticipatory governance: responding to challenges set by emerging technologies and innovation. Discussion Paper for the Study on Governance for Health in the 21st Century. Global Health Program, The Graduate Institute of International and Development Studies. Geneva: Switzerland, February 18, 2011.
47. Wynne B. Public engagement as a means of restoring public trust in science -- hitting the notes, but missing the music? Community Genet 2006; 9(3): 211-220.
48. Lehoux P. Moving beyond our mutual ignorance. Or, how would engaging the public benefit the personalized medicine community? Curr Pharmacogenomics Person Med 2011; 9(2): 76-79. Available from: http://www.benthamscience.com/openaccessplus.php?JCode=CPPM [Accessed June 27, 2011].
49. Nowotny H, Scott P, Gibbons M. Introduction: Mode 2 revisited: The new production of knowledge. Minerva 2003; 41(3): 179-194.
50. Oudshoorn N, Pinch T. How Users Matter: The Co-Construction of Users and Technology (Inside Technology). Boston: MIT Press 2003.
51. Barben D, Fisher E, Selin C, et al. Anticipatory governance of nanotechnology: Foresight, engagement and integration. In: The Handbook of Science and Technology Studies. Hackett EJ, Amsterdamska O, Lynch M, Wajcman J, Eds. Cambridge, MA: MIT Press 2008; pp. 979-1000.
52. Ozdemir V, Faraj SA, Knoppers BM. Steering vaccinomics innovations with anticipatory governance and participatory foresight. OMICS 2011 (in press).
53. Kickbusch I. Tackling the political determinants of global health. BMJ 2005; 331(7511): 246-247.
54. Kickbusch I. The Leavell lecture-the end of public health as we know it: constructing global public health in the 21st century. Public Health 2004; 188(7): 463-469.
55. Kamal SM, Warnich L, Ferguson LR, et al. Forward look: tenth anniversary of the human genome sequence and 21st century postgenomics global health - a close up on Africa and women's health. Curr Pharmacogenomics Person Med 2011; 9(3) (in press). Available from: http://www.benthamscience.com/openaccessplus.php?JCode=CPPM [Accessed June 27, 2011].
56. Khoury MJ., Muin J. Khoury discusses the future of public health genomics and why it matters for personalized medicine and global health. Curr Pharmacogenomics Person Med 2009; 7(3): 158-163. Available from: http://www.benthamscience.com/cppm/openaccessarticles/cppm7-3/003AF.pdf [Accessed June 27, 2011].
57. Corrigan OP. Personalized medicine in a consumer age. Curr Pharmacogenomics Person Med 2011; 9(3) (in press).